Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection

Pandey, Rajan Kumar; Ojha, Rupal; Aathmanathan, Veeranarayanan Surya; Krishnan, Muthukalingan; Prajapati, Vijay Kumar

doi:10.1016/j.vaccine.2018.03.042

Cited by 110 publications

(70 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The foreign gene expression may vary inside the host cell genome because of the mRNA codon inconsistency, thus, codon optimization is essential for higher expression [109]. Fortunately, both GC content and CAI value were great showing designating possible higher expression within E. coli K12 system.…”

Section: Discussionmentioning

confidence: 99%

Multiepitope-Based Subunit Vaccine Design and Evaluation against Respiratory Syncytial Virus Using Reverse Vaccinology Approach

et al. 2020

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is primarily associated with respiratory disorders globally. Despite the availability of information, there is still no competitive vaccine available for RSV. Therefore, the present study has been designed to develop a multiepitope-based subunit vaccine (MEV) using a reverse vaccinology approach to curb RSV infections. Briefly, two highly antigenic and conserved proteins of RSV (glycoprotein and fusion protein) were selected and potential epitopes of different categories (B-cell and T-cell) were identified from them. Eminently antigenic and overlapping epitopes, which demonstrated strong associations with their respective human leukocyte antigen (HLA) alleles and depicted collective ~70% coverage of the world’s populace, were shortlisted. Finally, 282 amino acids long MEV construct was established by connecting 13 major histocompatibility complex (MHC) class-I with two MHC class-II epitopes with appropriate adjuvant and linkers. Adjuvant and linkers were added to increase the immunogenic stimulation of the MEV. Developed MEV was stable, soluble, non-allergenic, non-toxic, flexible and highly antigenic. Furthermore, molecular docking and molecular dynamics (MD) simulations analyses were carried out. Results have shown a firm and robust binding affinity of MEV with human pathogenic toll-like receptor three (TLR3). The computationally mediated immune response of MEV demonstrated increased interferon-γ production, a significant abundance of immunoglobulin and activation of macrophages which are essential for immune-response against RSV. Moreover, MEV codons were optimized and in silico cloning was performed, to ensure its increased expression. These outcomes proposed that the MEV developed in this study will be a significant candidate against RSV to control and prevent RSV-related disorders if further investigated experimentally.

show abstract

Section: Discussionmentioning

confidence: 99%

Multiepitope-Based Subunit Vaccine Design and Evaluation against Respiratory Syncytial Virus Using Reverse Vaccinology Approach

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In this study, the helix forming linker 'EAAAK' was added to join the adjuvant and the first B-cell epitopes, while 'KK,' 'AAY,' and 'GPGPG' linkers were added to join together all B-cell epitopes, CTL epitopes and HTL epitopes, respectively. These linkers were appended to attain the efficient separation of individual epitopes in vivo [43].…”

Section: Vaccine Developmentmentioning

confidence: 99%

Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection

Mahapatra

Sahoo

Dehury

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

Background: The novel SARS-CoV-2 coronavirus, the causative agent of the ongoing pandemic COVID-19 disease continues to infect people globally and has infected millions of humans worldwide. However, no effective vaccine against this virus exists. Method: Using Immunoinformatics, epitopic sequences from multiple glycoproteins that play crucial role in pathogenesis were identified. Particularly, epitopes were mapped from conserved receptorbinding domain of spike protein which have been experimentally validated in SARS-CoV-1 as a promising target for vaccine development. Results: A multi-epitopic vaccine construct comprising of B-cell, CTL, HTL epitopes was developed along with fusion of adjuvant and linkers. The epitopes identified herein are reported for the first time and were predicted to be highly antigenic, stable, nonallergen, nontoxic and displayed conservation across several SARS-CoV-2 isolates from different countries. Additionally, the epitopes associated with maximum HLA alleles and population coverage analysis shows the proposed epitopes would be a relevant representative of large proportion of the world population. A reliable three-dimensional structure of the vaccine construct was developed. Consequently, docking and molecular-dynamics simulation ensured the stable interaction between vaccine and innate-immune receptor.

show abstract

“…S4). Among them, the model having the lowest energy score properly occupied the receptor 73 and found that the model number 11 was selected as the best-docked complex (Fig. 10).…”

Section: Molecular Docking Of Final Vaccine Construct With Tlr4 Immunmentioning

confidence: 99%

Computational Approach for Screening the Whole Proteome of Hantavirus and Designing a Multi-Epitope Subunit Vaccine

Abdulla

Nain

et al. 2019

Preprint

View full text Add to dashboard Cite

Hantaviruses are a newly zoonotic emerging group of rodent-borne viruses that have a significant impact on global public health by increasing amplitude and magnitude of outbreaks. As no permanent cure yet, it is now growing and challenging interest to develop a vaccine against Hantavirus. This study endeavored to design a robust subunit vaccine using a novel immunoinformatics approach. After meticulous evaluation, top ones from predicted CTL, HTL, and B-cell epitopes were considered as potential vaccine candidates. Among generated four vaccine models with different adjuvant, the model with TLR-4 agonist adjuvant was selected for its high antigenicity, non-allergenicity, and structural quality. The conformational B-cell epitope prediction assured its humoral response inducing ability. Thereafter, the molecular docking and dynamics simulation confirmed a good binding affinity with immune receptor TLR-4 and stability of the vaccine-receptor complex. In immune simulation, significantly high levels of IgM and IgG1 immunoglobulins, TC and TH-cell populations, and various cytokines (i.e. IFN-γ, IL-2 etc.) are coherence with actual immune response and also showed faster antigen clearance for repeated exposures. Finally, disulfide engineering enhanced vaccine stability and in silico cloning confirmed the better expression in E. coli K12. Nonetheless, experimental validation can proof the proposed vaccine's safety and ability to control Hantavirus infection.

show abstract

Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection

Cited by 110 publications

References 37 publications

Multiepitope-Based Subunit Vaccine Design and Evaluation against Respiratory Syncytial Virus Using Reverse Vaccinology Approach

Multiepitope-Based Subunit Vaccine Design and Evaluation against Respiratory Syncytial Virus Using Reverse Vaccinology Approach

Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection

Computational Approach for Screening the Whole Proteome of Hantavirus and Designing a Multi-Epitope Subunit Vaccine

Contact Info

Product

Resources

About